Floatz logo

Niclosamide

Recurrent Prostate Carcinoma

University of California, DavisSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

114 Active assets in the Recurrent Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Mayo Clinic
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Enzalutamide
Pfizer
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

Niclosamide is also rated in:

COVID-19Dormant
B
Indicative ·
61 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →